Welgene Biotech Co.,Ltd.

Taipei Exchange 6661.TWO

Welgene Biotech Co.,Ltd. Price to Book Ratio (P/B) on January 14, 2025: 1.80

Welgene Biotech Co.,Ltd. Price to Book Ratio (P/B) is 1.80 on January 14, 2025, a 0.46% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

Welgene Biotech Co.,Ltd. 52-week high Price to Book Ratio (P/B) is 2.83 on July 22, 2024, which is 57.23% above the current Price to Book Ratio (P/B).
Welgene Biotech Co.,Ltd. 52-week low Price to Book Ratio (P/B) is 1.67 on April 16, 2024, which is -7.32% below the current Price to Book Ratio (P/B).
Welgene Biotech Co.,Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is 1.89.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Taipei Exchange: 6661.TWO

Welgene Biotech Co.,Ltd.

CEO	Dr. Yi Xing Lin
IPO Date	Oct. 23, 2017
Location	Taiwan
Headquarters	No. 3, Yuanyuan Street
Employees	80
Sector	Health Care
Industries Biotechnology Research & Consulting

Description

Welgene Biotech Co.,Ltd. provides genetic testing services. The company offers research services, including sequencing, microarray, qPCR verification, nucleic acid extraction/QC, LCM single cell experiment, and bioinformatics analysis services; and Cytoscan, an array-based comparative genomic hybridization. It also provides reagents, consumable supplies, and instruments, as well as software services. The company was founded in 2003 and is based in Taipei City, Taiwan.

Key trends

Past 5 years